A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients (Q2861803): Difference between revisions

@@ Property / MaRDI profile type @@
+MaRDI publication profile
@@ Property / MaRDI profile type: MaRDI publication profile / rank @@
+Normal rank
@@ Property / OpenAlex ID @@
+W2019966306
@@ Property / OpenAlex ID: W2019966306 / rank @@
+Normal rank
@@ Property / cites work @@
+Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
+Normal rank
@@ Property / cites work @@
+Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
+Normal rank
@@ Property / cites work @@
+Analysis of multivariate survival data
@@ Property / cites work: Analysis of multivariate survival data / rank @@
+Normal rank
@@ Property / cites work @@
+Optimal Dynamic Treatment Regimes
@@ Property / cites work: Optimal Dynamic Treatment Regimes / rank @@
+Normal rank
@@ Property / cites work @@
+Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
+Normal rank
@@ Property / cites work @@
+AMCMC: an R interface for adaptive MCMC
@@ Property / cites work: AMCMC: an R interface for adaptive MCMC / rank @@
+Normal rank
@@ Property / cites work @@
+A nonidentifiability aspect of the problem of competing risks.
+Normal rank
@@ Property / cites work @@
+Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
+Normal rank
@@ links / mardi / name / links / mardi / name @@
+Publication:2861803